BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an ...
While travelers rush home to relatives or back from essential business visits, AI is quietly rewiring how bags move, fl ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback